Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Summary

The purpose is to observe and evaluate the safety and effectiveness of anlotinib in children with progressive, recurrent, and refractory sarcoma. Pharmacokinetics was also detected.

Timeline

Start

2020-12-30

Primary completion

2022-12-15

Completion

2022-12-30

Publications

• Lu S, Que Y, Liu D, Sun F, Yao X, Deng L, Zhan J, Huang J, Cai R, Wang X, Zhu S, Zhen Z, Zhu J, Wang J, Zhang Y. Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial. EClinicalMedicine. 2025 May 23;84:103258. doi: 10.1016/j.eclinm.2025.103258. eCollection 2025 Jun.

Drugs

Indications